A Study Evaluating HS-10370 Plus Platinum-based Doublet Chemotherapy With or Without Adebrelimab vs. Tislelizumab Plus Chemotherapy as First-Line Therapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
NCT07822542
Study timeline
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
What this registered study describes
A Study Evaluating HS-10370 Plus Platinum-based Doublet Chemotherapy With or Without Adebrelimab vs. Tislelizumab Plus Chemotherapy as First-Line Therapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer is a interventional study listed under registry identifier NCT07822542. Its last published status is NOT YET RECRUITING. Registry status does not establish that enrollment is currently open at every study site.
The published record lists 1 condition label(s), 6 intervention label(s), and 1 sponsor/collaborator entry or entries. The structured information below allows these links to be examined individually; intervention registration is not an efficacy claim.
Source: the original ClinicalTrials.gov study record. Always check the protocol, eligibility, dates, results (when posted), and contacts at the original source.
Conditions
Interventions
Sponsors & collaborators
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT07822542 on ClinicalTrials.gov ↗How to interpret this record
CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.